BOULDER, Colo.--(BUSINESS WIRE)--Havah Therapeutics, a clinical stage biopharmaceutical company developing innovative, proprietary hormonal implant therapies for prevention and treatment of breast cancers, announced the formation of their Clinical Advisory Board Chaired by Havah Therapeutics founder Stephen Birrell, MD, PhD..

科罗拉多州博尔德市——（商业新闻短讯）——临床阶段生物制药公司Havah Therapeutics宣布成立临床咨询委员会，由Havah Therapeutics创始人Stephen Birrell博士担任主席，该公司开发创新的专有激素植入疗法，用于预防和治疗乳腺癌。。

“The scientific and clinical guidance of this esteemed group will be invaluable as we advance our androgen targeted therapy into late-stage clinical studies for Ductal Carcinoma In-Situ (DCIS) and investigator-sponsored combination studies in more advanced disease,” said, Matthew Brewer, CEO of Havah Therapeutics..

Havah Therapeutics首席执行官马修·布鲁尔（MatthewBrewer）表示：“随着我们将雄激素靶向治疗推进导管原位癌（DCIS）的晚期临床研究和研究者赞助的更晚期疾病联合研究，这一备受尊敬的小组的科学和临床指导将是非常宝贵的。”。。

Shelley Hwang, MD, MPH, Breast Cancer Research Foundation (BCRF) Investigator and internationally recognized expert in pre-invasive disease and DCIS, added: “I am thrilled to be involved with Havah Therapeutics at this critical stage of their development. Insights gained from their ongoing Phase 2 study (RECAST DCIS), coupled with my experience as the principal investigator of the COMET Study, will potentially enable the company’s androgen receptor targeting therapy to provide a much needed treatment alternative to invasive surgery and radiation treatment.”.

乳腺癌研究基金会（BCRF）研究员、国际公认的侵袭前疾病和DCIS专家Shelley Hwang医学博士、公共卫生硕士补充道：“我很高兴在Havah治疗的发展的关键阶段参与到Havah治疗中。从他们正在进行的第二阶段研究（RECAST DCIS）中获得的见解，加上我作为COMET研究首席研究员的经验，将有可能使该公司的雄激素受体靶向治疗能够为侵入性手术和放射治疗提供急需的治疗替代方案。”。

The members of Havah Therapeutics’ Clinical Advisory Board include:

Havah Therapeutics临床咨询委员会的成员包括：

Stephen Birrell, MD, PhD (Chair), is founder of Havah Therapeutics and Chief Medical Officer of Wellend Health, an Australia-wide clinic that specializes in breast hormone-health, women at high-risk breast cancer and clinical trials. He is a Clinical Affiliate academic at the University of Adelaide Dame Roma Mitchell Cancer Research Laboratories..

Stephen Birrell，医学博士，博士（主席），是Havah Therapeutics的创始人和Wellend Health的首席医疗官，Wellend Health是一家澳大利亚范围的诊所，专门从事乳腺激素健康，高危乳腺癌女性和临床试验。他是阿德莱德大学罗马夫人米切尔癌症研究实验室的临床附属学者。。

Shelley Hwang, MD, MPH is the Mary and Deryl Hart Distinguished Professor of Surgical Oncology and Radiology, Vice Chair of Research and Disease Group Leader for the Breast Cancer Program at Duke University Comprehensive Cancer Center. Her research focus includes breast cancer prevention, identifying less invasive treatments for early-stage breast cancers including DCIS and addressing and mitigating health care disparities in breast cancer..

Shelley Hwang医学博士，公共卫生硕士，玛丽和德丽尔·哈特外科肿瘤学和放射学杰出教授，杜克大学综合癌症中心乳腺癌项目研究和疾病小组负责人副主席。她的研究重点包括乳腺癌预防，确定包括DCIS在内的早期乳腺癌的微创治疗方法，以及解决和缓解乳腺癌的医疗保健差异。。

Seema A. Khan, MD is Professor of Surgery in the Feinberg School of Medicine at Northwestern University, and the Bluhm Family Professor of Cancer Research. She is the Co-Leader of the Cancer Prevention Research Program at the Robert H. Lurie Comprehensive Cancer Center. Her research focuses on applying biomarker knowledge to improve breast cancer risk stratification and develop preventive interventions for high-risk women.

医学博士SeemaA.Khan是西北大学范伯格医学院外科教授，也是Bluhm家族癌症研究教授。她是罗伯特·H·卢里综合癌症中心癌症预防研究项目的联合负责人。。

Her research is funded by the National Institutes of Health, The Breast Cancer Research Foundation, the Avon Foundation, and the Susan G. Komen Foundation.

她的研究由美国国立卫生研究院、乳腺癌研究基金会、雅芳基金会和苏珊·G·科门基金会资助。

Professor Wayne Tilley, PhD is the Inaugural Director of the Dame Roma Mitchell Cancer Research Laboratories, University of Adelaide. He completed a Fellowship at UT Southwestern in Dallas Texas in the late 1980s where he was one of the first to clone the human androgen receptor (AR) with Professor Jean Wilson, MD.

韦恩·蒂利教授（WayneTilley）博士是阿德莱德大学罗玛·米切尔夫人癌症研究实验室（Dame Roma Mitchell Cancer Research Laboratories）的首任主任。20世纪80年代末，他在德克萨斯州达拉斯的UT西南大学（UTSouthwestern）完成了一项奖学金，在那里他是第一个与医学博士让·威尔逊（Jean Wilson）教授克隆人类雄激素受体（AR）的人之一。

A current major research focus of Professor Tilley’s lab is the development of new treatments for breast cancer that stimulate the tumor suppressive activity of the AR in the breast (Nature Medicine 2021; Lancet Oncology 2024) to counter the proliferative effects of estrogen..

蒂利教授实验室目前的一个主要研究重点是开发乳腺癌的新疗法，刺激乳腺中AR的肿瘤抑制活性（Nature Medicine 2021；Lancet Oncology 2024），以对抗雌激素的增殖作用。。

Additional background information on the CAB members can be found on the company’s website: www.havahtx.com

有关CAB成员的其他背景信息，请访问该公司的网站：www.havahtx.com

About RECAST DCIS

关于重铸DCIS

Havah Therapeutics is currently participating in the Re-Evaluating Conditions for Active Surveillance Suitability as Treatment: Ductal Carcinoma In Situ (RECAST DCIS), a Phase 2 platform study aimed at preventing the progression of DCIS to breast cancer. Havah Therapeutics’ HAVAH T+Ai™, a proprietary combination of testosterone (T) and anastrozole (Ai) that targets the androgen and estrogen receptor pathways, is being evaluated alongside two other endocrine therapy arms..

Havah Therapeutics目前正在参与重新评估主动监测作为治疗适宜性的条件：原位导管癌（RECAST DCIS），这是一项旨在预防DCIS进展为乳腺癌的2期平台研究。Havah Therapeutics的Havah T+Ai™是针对雄激素和雌激素受体途径的睾酮（T）和阿那曲唑（Ai）的专有组合，正在与其他两个内分泌治疗组一起进行评估。。

About Havah Therapeutics

关于Havah Therapeutics

Havah Therapeutics is developing a novel therapeutic implant for treating hormonally sensitive cancers and other breast conditions. This groundbreaking method relies on stimulating (agonizing) the androgen receptor in breast tissue, utilizing natural hormonal mechanisms to treat patients safely and with greatly reduced side effects.

Havah Therapeutics正在开发一种新型治疗植入物，用于治疗激素敏感的癌症和其他乳腺疾病。这种开创性的方法依赖于刺激（激动）乳腺组织中的雄激素受体，利用天然激素机制安全治疗患者，并大大减少副作用。

The product is a combination of two registered agents (testosterone and anastrozole, a low dose aromatase inhibitor) that when dosed, provides three months of continuous medication enabling a superior product profile for compliance, safety and efficacy. For more information, visit www.havahtx.com..

该产品是两种注册药物（睾酮和阿那曲唑，一种低剂量芳香化酶抑制剂）的组合，当给药时，可提供三个月的连续用药，从而在依从性，安全性和有效性方面具有优异的产品特征。有关更多信息，请访问www.havahtx.com。。